Alleviation of ischemic neuronal damage by histamine H2 receptor stimulation in the rat striatum

Transient ischemia was produced for 15 min by occlusion of the middle cerebral artery in halothane-anesthetized rats, and changes in the extracellular concentrations of neurotransmitter monoamines and amino acids were examined in the striatum. The occlusion produced marked increases in the extracellular concentrations of both dopamine and glutamate in the striatum in the saline-injected control group, the peak values being 148 and 5.2 times those before ischemia, respectively. Preischemic administration of histamine (200 nmol, i.c.v.) suppressed the increase in dopamine and glutamate levels during ischemia, the peak values being 38% and 40% of those in the control group, respectively. Neither the dopamine nor glutamate level was affected by 6-[2-(4-imidazolyl)ethylamino]-N-(trifluoromethylphenyl)heptanecarboxamide (HTMT), an H(1) agonist (100 nmol, i.c.v.). However, dimaprit, an H(2) agonist (100 nmol, i.c.v.) suppressed the peak values to 42% and 32%, respectively. Most neurons were degenerated 7 days after ischemia in control animals. Histologic outcome was alleviated by either histamine or dimaprit treatment, whereas HTMT did not affect the outcome. Although postischemic administration of mepyramine, an H(1) antagonist (5 nmol, i.c.v.), did not affect the histologic alleviation caused by preischemic treatment with histamine, ranitidine, an H(2) antagonist (30 nmol, i.c.v.), partly abolished the improvement caused by histamine. These results suggest that suppression of ischemic release of excitatory neurotransmitters by histamine H(2) action is a contributing factor in alleviation of histologic outcome.     

Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats

Inflammatory reactions play an important role in ischemia/reperfusion injury in various organs. Since histamine is closely related to inflammatory reactions and immune responses, effects of postischemic administration of histaminergic ligands on ischemia-induced liver injury were examined in rats. Animals were subjected to warm ischemia for 30 min by occlusion of the left portal vein and hepatic artery under halothane anesthesia, and liver damage was evaluated by assessing plasma concentrations of transaminases after 24 h. Warm ischemia for 30 min provoked severe liver damage after 24 h, and the plasma concentrations of alanine transaminase (ALT) and aspartate transaminase (AST) were 8600 I.U./l and 13100 I.U./l, respectively. Subcutaneous injections of histamine twice, immediately and 6 h after reperfusion (20 mg/kg, each), alleviated liver damage. The plasma concentrations of ALT and AST in the histamine group were 35% and 24% of those in the control group, respectively. Neither mepyramine (3 mg/kg x 2), an H1 antagonist, nor cimetidine (15 mg/kg x 2), an H2 antagonist, affected the outcome in histamine-treated rats. However, thioperamide (5 mg/kg x 2), an H3/H4 antagonist, completely abolished the alleviation caused by histamine. Administration of dimaprit (1-10 mg/kg x 2), an H2/H4 agonist, mimicked the protective effect of histamine, and the effect of dimaprit is reversed by thioperamide, whereas neither H1 nor H2 antagonists altered the outcome caused by dimaprit. Clozapine (15 mg/kg x 2), an H4 agonist, also mimicked the protective effect of histamine. These findings indicate that stimulation of histamine H4 receptors after ischemic events prevents development of reperfusion injury in the liver.     

Protein kinase C inhibits stimulation of adenylate cyclase by the histamine H2 receptor in rat parietal cells.

The action of protein kinase C on the stimulation of adenylate cyclase activity by the histamine H2 receptor was investigated in rat parietal cells. Protein kinase C was activated by preincubating cells with 12-O-tetradecanoylphorbol 13-acetate (TPA), and adenylate cyclase activity was measured in sonicated extracts. TPA (100 nM) inhibited adenylate cyclase activity stimulated by histamine (100 nM-500 microM). This effect was related to the concentration of TPA. TPA (100 nM) enhanced the stimulation of adenylate cyclase activity by forskolin (100 microM) but had no effect on the stimulation by NaF (10 mM). In conclusion, protein kinase C inhibits stimulation of adenylate cyclase by the histamine H2 receptor. This action could be mediated by changes in the number of affinity of histamine H2 receptors or in the coupling of the receptor to the stimulatory guanine nucleotide regulatory subunit Gs.     

Neuro-glio-vascular interaction in ischemic brains

The brain contains glial cells (astrocytes, microglia, and oligodendrocytes) and endothelial cells in addition to neurons. Under various pathologic conditions, the invasion of leukocytes such as neutrophils, monocytes/macrophages, and lymphocytes is observed. Interactions among these cell types play crucial roles both in brain function and dysfunction. However, the molecular basis of such interactions remains unclear. Cytokines and chemokines were originally identified as essential mediators of inflammatory and immune responses. Enhanced production and release of cytokines/chemokines are observed also in the central nervous system under various pathologic conditions. There is growing evidence showing that brain cytokines/chemokines play crucial roles in the neuro-glio-vascular interaction underlying the pathology of various brain disorders and therefore are potential targets for the development of novel and effective therapeutics for central nervous system diseases. This article reviews the evidence for the involvement of cytokines/chemokines in ischemic brain injury and presents our data on introducing organotypic brain slice cultures and in vitro blood brain barrier models as useful tools to investigate neuro-glio-vascular interaction.     

The therapeutic potential of histamine receptor ligands in inflammatory bowel disease

In the intestine of patients suffering from inflammatory bowel disease concentrations of histamine are increased compared to healthy controls. Genetic ablation of histamine production in mice ameliorates the course of experimentally induced colitis. These observations and first pharmacological studies indicate a function of histamine in the pathogenesis of inflammatory bowel disease. However, a closer examination reveals that available data are highly heterogeneous, limiting the rational design of strategies addressing specific histamine receptor subtypes as possible target for pharmacological interaction. However, very recently first clinical data indicate that antagonism at the histamine receptor subtype H₄ provides a beneficial effect in at least the skin. Here, we discuss the available data on histamine effects and histamine receptor subtype functions in inflammatory bowel disease with a special emphasis on the histamine H₄-receptor.     

The role of histamine H4 receptor in immune and inflammatory disorders

Since its discovery at the beginning of the 20th century, histamine has been established to play a pathophysiological regulatory role in cellular events through binding to four types of G-protein-coupled histamine receptors that are differentially expressed in various cell types. The discovery, at the turn of the millennium, that the histamine H₄ receptor is largely expressed in haemopoietic cells as well as its chemotactic properties designate its regulatory role in the immune system. H₄ receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H₄ receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function. The characterization of the H₄ as the immune system histamine receptor directed growing attention towards its therapeutic exploitation in inflammatory disorders, such as allergy, asthma, chronic pruritus and autoimmune diseases. The efficacy of a number of H₄ receptor ligands has been evaluated in in vivo and in vitro animal models of disease and in human biological samples. However, before reaching decisive conclusions on H₄ receptor pathophysiological functions and therapeutic exploitation, identification of genetic polymorphisms and interspecies differences in its relative actions and pharmacological profile need to be addressed and taken into consideration. Despite certain variations in the reported findings, the available data strongly point to the H₄ receptor as a novel target for the pharmacological modulation of histamine-transferred immune signals and offer an optimistic perspective for the therapeutic exploitation of this promising new drug target in inflammatory disorders.     

Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: Suppression by α2-Adrenoceptor stimulation

The anti-withdrawal effect of clonidine was studied using quasi-morphine abstinence behaviour induced by dipropylacetate (DPA) in naive rats. Clonidine potently suppressed body shakes and locomotor activity (ID50 30 and 40 micrograms/kg IP respectively). Phenoxybenzamine and prazosine did not antagonize the anti-withdrawal effect of clonidine, whereas piperoxane and yohimbine were effective with respect to locomotor activity and a total abstinence score. Piperoxane also reversed the suppressive action of clonidine on body shakes. Other alpha 2-agonists (guanfacine, azepexole and BHT 920) also suppressed DPA-induced behaviour, whereas the lipophilic alpha 1-agonist ST-587 had such an effect only at high doses. The relative potencies of the alpha 2-agonists correlated well with their potency to exert other alpha 2-adrenoceptor mediated actions such as blood pressure lowering and sedation.     

山莨菪碱对脑缺血局部血流量的影响

用放射性生物微球法,观察了山莨菪碱对双侧颈总动脉结扎(BCAL)后大鼠脑局部血流量的影响.BCAL使大鼠大脑半球血流量显著减少,以中部最明显。山莨菪减10mg·kg~(-1)iv明显增加缺血最严重的大脑中部血流量,20mg·kg~(-1)iv明显增加整个大脑半球血流量,40mg·kg~(-1)iv则作用减弱。BCAL后心肌血流量明显增加,山莨菪碱20mg·kg~(-1)iv使其进一步增加,但40mg·kg_(-1)iv则使其显著减少。10～20·mg·kg~(-1)iv对BCA L后的心指数无明显影响,40mg·kg~(-1)iV则使其明显增大。     

Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor.

1. We have shown that intracisternal (i.c.) administration of interleukin-1 beta (IL-1 beta) attenuates naloxone-precipitated withdrawal jumps in morphine-dependent mice, and the effect was partly mediated by the corticotropin-releasing factor. To elucidate further other possible mechanisms involved in the inhibitory effect of IL-1 beta on morphine withdrawal jumping behaviour, in this study, we examined the involvement of the prostaglandin-synthesis pathway, because prostaglandins have been shown to mediate the several central effects of IL-1. Furthermore, we examined the effects of subtype-selective prostaglandin receptor agonists on morphine withdrawal jumping behaviour. 2. Mice were rendered morphine-dependent by subcutaneous implantation of a pellet containing 11.5 +/- 0.3 mg morphine hydrochloride for 48 h. Morphine withdrawal syndromes were precipitated by intraperitoneal (i.p.) injection of naloxone (10 mg kg-1). The degree of physical dependence on morphine was estimated by counting the number of jumps, one of the typical withdrawal signs in mice, for 40 min. 3. The inhibitory effect of IL-1 beta (1 ng/mouse) administered intracisternally 30 min before naloxone (10 mg kg-1, i.p.) was significantly blocked by pretreatment with sodium salicylate (a cyclo-oxygenase inhibitor, 10 ng or 30 ng/mouse) administered intracisternally 15 min before IL-1 beta, while i.c. administration of sodium salicylate alone (3 ng, 10 ng or 30 ng/mouse) followed by i.c. administration of vehicle instead of IL-1 beta did not significantly change the number of jumps precipitated by naloxone. 4. Intracisternal administration of M&B28,767 (an EP3-receptor agonist, 1 fg-30 ng/mouse) and sulprostone (an EP1/EP3-receptor agonist, 10 fg-100 ng/mouse) 30 min before naloxone (10 mg kg,-1 i.p.) attenuated withdrawal jumps with a U-shaped dose-response, reaching a peak at 10 pg/mouse and 100 pg/mouse, respectively. On the other hand, i.c. administration of iloprost (an EP1/IP-receptor agonist, 10 fg-100 ng/mouse), butaprost (an EP2-receptor agonist, 10 fg-100 ng/mouse) or prostaglandin F2 alpha (a FP-receptor agonist, 10 fg-100 ng/mouse) 30 min before naloxone (10 mg kg-1, i.p.) did not significantly change the number of jumps precipitated by naloxone. 5. These results indicate that the prostaglandin-synthesis pathway is, at least in part, involved in the inhibitory effect of IL-1 beta on naloxone-precipitated withdrawal jumps in morphine-dependent mice, and that the prostaglandin synthesized in the brain suppresses the morphine withdrawal jumping behaviour via the EP3-receptor, but not via the EP1-, EP2-, IP- or FP-receptor.     

kappa-opioid receptor stimulation inhibits cardiac hypertrophy induced by beta1-adrenoceptor stimulation in the rat

To test the hypothesis that kappa-opioid receptor stimulation inhibits cardiac hypertrophy induced by beta1-adrenoceptor stimulation, we determined the effects of trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide methanesulfonate salt (U50,488H), a selective kappa-opioid receptor agonist, on cardiac hypertrophy induced by isoprenaline, a selective beta-adrenoceptor agonist, in neonatal ventricular myocytes upon blockade of beta2-adrenoceptor. Hypertrophy of cardiomyocytes was determined by increases in (i) total protein content; (ii) [3H]leucine incorporation; and iii) cell size. 10 micromol/l isoprenaline increased all three parameters. The effects were abolished by 2 micromol/l propranolol, a beta-adrenergic receptor antagonist, or 300 nmol/l CGP20712A, a beta1-adrenoceptor antagonist, but not by 100 nmol/l ICI118,551, a beta2-adrenoceptor antagonist. The effects were also abolished by Rp-cAMPs 100 micromol/l, a protein kinase A inhibitor and not by pertussis toxin 5 mg/l. The effects of isoprenaline in the presence or absence of ICI118,551 were also abolished by 1 micromol/l U50,488H. The inhibitory effects of U50,488H were abolished by 1 micromol/l nor-binaltorphimine, a selective kappa-opioid receptor antagonist. U50,488H also abolished the increases in the amplitude and frequency of the spontaneous intracellular Ca2+ transient induced by 10 micromol/l isoprenaline in the presence or absence of ICI118,551, an effect also abolished by nor-binaltorphimine. In conclusion the results show that kappa-opioid receptor stimulation abolished both the cardiac hypertrophy and enhanced amplitude and frequency of the spontaneous intracellular Ca2+ transient induced by beta1-adrenoceptor stimulation.     

Inhibition of gastric acid secretion by adenosine receptor stimulation in the rat

The effects of adenosine and its metabolically stable derivative L-phenylisopropyladenosine (L-PIA), acting mainly on A1 receptors, on gastric acid secretion were studied in the rat. Although inactive by intraduodenal route, subcutaneous adenosine significantly inhibited acid secretion. This inhibition, however, was not dose-dependent. On the contrary, L-PIA was able to decrease dose-dependently acid output by both subcutaneous and intraduodenal route, its ED50 being 0.11 mg/kg subcutaneously and 0.24 mg/kg intraduodenally. The inhibitory effect of L-PIA was reduced by prior administration of theophylline. These results suggest that activation of A1-receptors inhibits acid secretion in the rat.     

Clonidine decreases rat urine kallikrein excretion by alpha-adrenergic receptor stimulation

In normal conscious female Sprague-Dawley rats, clonidine dose-dependently (10-300 micrograms/kg) decreased urine kallikrein excretion to approximately 40% of the control value. The effect of clonidine on urine enzyme excretion was inversely related to diuresis-natriuresis. Phenoxybenzamine (1 mg/kg) or phentolamine (10 mg/kg) antagonized the effect of clonidine on urine enzyme excretion. Consequently, rat urine kallikrein excretion might be reduced when alpha-adrenergic receptors are stimulated by clonidine.     

Suppression of lordotic responsiveness in the female rat during mesencephalic electrical stimulation

The effects of biphasic electrical stimulation of the mesencephalic median (MRN) and dorsal raphe (DRN) nuclei, as well as the adjacent periaqueductal gray (PAG), on lordotic behavior were investigated in ovariectomized rats primed with three daily injections of estradiol benzoate (2 micrograms). Animals were tested between 4-8 hours after a progesterone (0.5 mg) injection on day four which normally facilitates high levels of receptivity during this period. Although stimulation of the MRN had no significant effect on lordosis, DRN activation at 100 Hz (0.5 msec pulse duration) or 10 Hz (2 msec pulse duration) caused a marked and immediate suppression (53% and 56%, respectively) in receptivity. This suppression does not appear to be due to activation of serotoninergic neurons originating in the DRN since pretreatment with an inhibitor of serotonin synthesis (parachlorophenylalamine, 320 mg/kg) essentially did not modify the suppression, thus providing no evidence in support of an inhibitory role for serotonin in lordotic behavior. Activation within the PAG adjacent to the DRN at 10 Hz (0.5 or 2 msec pulse duration) produced an immediate, dramatic decrease (81% and 80%, respectively) in receptivity. The suppressions induced by DRN and PAG stimulation appear most likely to be due to activation of a descending pathway inhibitory to the lordosis reflex at medullary or spinal cord levels.     

Effect of H2 histamine receptor blockade and stimulation on urinary acidification

Acid secretion by the stomach is enhanced by H2 histamine stimulation and is depressed by its inhibition. The present investigation was undertaken to assess the possible effect of H2 histamine activity on acid excretion by the kidney, the other major acid secreting organ. The study was stimulated by an earlier observation indicating a fall in urinary acid excretion in human associated with short-term administration of an H2 histamine antagonist (cimetidine). Female Sprague-Dawley rats were randomly assigned to the cimetidine-treated, histolog-treated and placebo-treated (control) groups. Urinary titratable acidity, NH4+, HCO3- and net acid excretion rates were determined following administration of either cimetidine, histolog or placebo. Excepting the above pharmacologic manipulations all other experimental conditions were similar. Urinary titratable and net acid excretion rates were significantly reduced with cimetidine and increased with histalog as compared with the control group. The observed urinary changes are not due to the effects of these agents on gastric acid secretion since if that was the case the opposite results would have been expected. The data suggest that urinary acidification is somehow influenced by acute changes of H2 histamine activity in rats. The precise mechanism, site of action in the kidney and pathophysiologic significance of this phenomenon remains to be elucidated.     

Autoinhibition of histamine release by H3 receptors in rat brain cortex depends on stimulation frequency.

Rat cortical slices preloaded with [3H]histidine released [3H]histamine upon electrical stimulation or after depolarization with elevated K+ levels. The release was dependent on the presence of Ca2+, suggesting a neurosecretory process. Histamine has been shown to inhibit its own release mediated by an autoreceptor belonging to the H3-receptor subclass. In this study we have investigated the autoinhibition using different electrical field stimulation conditions (1, 10, 20 and 33.3 Hz). Applying electrical stimulation, the inhibition of [3H]histamine release by histamine is decreased when the stimulation frequency is elevated. When stimulated with 1 Hz histamine is able to block [3H]histamine release completely, with a p(EC50) of 8.1 +/- 0.1. At higher frequencies histamine still blocks [3H]histamine release completely, but with a lower p(EC50).     

Suppression of ethanol-induced locomotor stimulation by GABA-like drugs

Summary Ethanol (2.4 g/kg) was given intraperitoneally to mice and was found to cause a marked increase in spontaneous locomotor activity. When mice were pretreated with low doses of agents which mimic or augment the action of GABA (-hydroxybutyric acid, baclophen, or aminooxyacetic acid) the ethanol-induced locomotor stimulation was completely eliminated. Baclophen (10 mg/kg) was found to cause an initial increase followed by a later decrease in synthesis of catecholamines, as measured by the accumulation of dopa after inhibition of central aromatic l-amino acid decarboxylase, in dopamine-rich areas of rat brain. These data are consistent with previous findings that baclophen, as well as other agents which enhance the activity of GABA systems, reduce the firing of dopamine neurons, thus causing enhanced synthesis of dopamine via feedback mechanisms. These findings also indicate a potential interaction between GABA-like drugs and alcohol in man, and may be of heuristic value in the treatment of chronic alcoholism. The possibility that the mechanism of the inhibition of ethanol-induced locomotor stimulation by GABA-like drugs may be due to a selective interference with ethanol-induced dopamine release is discussed.     

Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1

Aim:

To investigate the neuroprotective effect of glycyrrhizin (Gly) against the ischemic injury of rat spinal cord and the possible role of the nuclear protein high-mobility group box 1 (HMGB1) in the process.

Methods:

Male Sprague-Dawley rats were subjected to 45 min aortic occlusion to induce transient lumbar spinal cord ischemia. The motor functions of the animals were assessed according to the modified Tarlov scale. The animals were sacrificed 72 h after reperfusion and the lumbar spinal cord segment (L2–L4) was taken out for histopathological examination and Western blotting analysis. Serum inflammatory cytokine and HMGB1 levels were analyzed using ELISA.

Results:

Gly (6 mg/kg) administered intravenously 30 min before inducing the transient lumbar spinal cord ischemia significantly improved the hind-limb motor function scores, and reduced the number of apoptotic neurons, which was accompanied by reduced levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in the plasma and injured spinal cord. Moreover, the serum HMGB1 level correlated well with the serum TNF-α, IL-1β and IL-6 levels during the time period of reperfusion.

Conclusion:

The results suggest that Gly can attenuate the transient spinal cord ischemic injury in rats via reducing inflammatory cytokines and inhibiting the release of HMGB1.     

Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography.

1. Histamine H1 receptor occupancy in the human brain was measured in 20 healthy young men by positron emission tomography (PET) using [11C]-doxepin. 2. (+)-Chlorpheniramine, a selective and classical antihistamine, occupied 76.8 +/- 4.2% of the averaged values of available histamine H1 receptors in the frontal cortex after its administration in a single oral dose of 2 mg. Intravenous administration of 5 mg (+)-chlorpheniramine almost completely abolished the binding of [11C]-doxepin to H1 receptors (H1 receptor occupancy: 98.2 +/- 1.2%). 3. Terfenadine, a nonsedative antihistamine, occupied 17.2 +/- 14.2% of the available H1 receptors in the human frontal cortex after its administration in a single oral dose of 60 mg. 4. There was no correlation between H1 receptor occupancy by terfenadine and the plasma concentration of the active acid metabolite of terfenadine in each subject. 5. PET data on human brain were essentially compatible with those on H1 receptor occupancy in guinea-pig brain determined by in vivo binding techniques, although for the same H1 receptor occupancy the dose was less in human subjects than in guinea-pigs. 6. The PET studies demonstrated the usefulness of measuring H1 receptor occupancy with classical and second-generation antihistamines in human brain to estimate their unwanted side effects such as sedation and drowsiness quantitatively.